875337-44-3

Solubility:DMSO

Storage:at -20℃ 2 years

Biologieal

MGCD265 is a tyrosine kinase inhibitor that targets the MET, VEGFR-1, VEGFR-2, VEGFR-3, RON and TIE2 receptor tyrosine kinases, which appear to play key roles in tumour development and blood vessel formation (angiogenesis) and tumour survival. MGCD265 is currently in phase I single-agent clinical trials for solid tumour cancers and in phase II trials for solid tumours and NSCLC .

Reference

[1] Cañadas I et al. Clin Transl Oncol. 2010 Apr;12(4):253-60